K
Kym N Lowes
Researcher at Walter and Eliza Hall Institute of Medical Research
Publications - 38
Citations - 3279
Kym N Lowes is an academic researcher from Walter and Eliza Hall Institute of Medical Research. The author has contributed to research in topics: Plasmodium falciparum & Medicine. The author has an hindex of 19, co-authored 31 publications receiving 2706 citations. Previous affiliations of Kym N Lowes include Fremantle Hospital & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson,Darren C. Phillips,Michael J. Mitten,Erwin R. Boghaert,Dolores Diaz,Stephen K. Tahir,Lisa D. Belmont,Paul Nimmer,Yu Xiao,Xiaoju Max Ma,Kym N Lowes,Kym N Lowes,Peter Kovar,Jun Chen,Sha Jin,Morey L. Smith,John Xue,Haichao Zhang,Anatol Oleksijew,Terrance J. Magoc,Kedar S. Vaidya,Daniel H. Albert,Jacqueline M. Tarrant,Nghi La,Le Wang,Zhi-Fu Tao,Michael D. Wendt,Deepak Sampath,Saul H. Rosenberg,Chris Tse,David C.S. Huang,David C.S. Huang,Wayne J. Fairbrother,Steven W. Elmore,Andrew J. Souers +34 more
TL;DR: BCL-XL–selective inhibitors have the potential to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax, and demonstrate the translational utility of this toolkit of selective BCL-2 family inhibitors.
Journal ArticleDOI
Oval Cell Numbers in Human Chronic Liver Diseases Are Directly Related to Disease Severity
TL;DR: There is an association between severity of liver disease and increase in the number of oval cells consistent with the hypothesis that oval cell proliferation is associated with increased risk for development of hepatocellular carcinoma in chronic liver disease.
Oval Cell Numbers in Human Chronic Liver Diseases are directly related to Disease Severity
TL;DR: In this article, the authors found that the risk of developing hepatocellular carcinoma is significantly increased in patients with genetic hemochromatosis, alcoholic liver disease, or chronic hepatitis C infection.
Journal ArticleDOI
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene,Guillaume Lessene,Peter E. Czabotar,Peter E. Czabotar,Brad E. Sleebs,Brad E. Sleebs,Kerry Zobel,Kym N Lowes,Kym N Lowes,Jerry M. Adams,Jerry M. Adams,Jonathan B. Baell,Jonathan B. Baell,Jonathan B. Baell,Peter M. Colman,Peter M. Colman,Kurt Deshayes,Wayne J. Fairbrother,John A. Flygare,Paul Gibbons,Wilhelmus J A Kersten,Wilhelmus J A Kersten,Sanjitha Kulasegaram,Sanjitha Kulasegaram,Sanjitha Kulasegaram,Rebecca M Moss,Rebecca M Moss,John P Parisot,John P Parisot,John P Parisot,Brian J. Smith,Brian J. Smith,Brian J. Smith,Ian P. Street,Ian P. Street,Hong Yang,Hong Yang,David C.S. Huang,David C.S. Huang,Keith G. Watson,Keith G. Watson +40 more
TL;DR: The optimized compound, WEHI-539 (7), has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity.
Journal ArticleDOI
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Theresa Klemm,Gregor Ebert,Dale J Calleja,Cody C. Allison,Lachlan W Richardson,Jonathan P. Bernardini,Jonathan P. Bernardini,Bernadine Gc Lu,Nathan W Kuchel,Christoph Grohmann,Yuri Shibata,Zhong Yan Gan,James P Cooney,Marcel Doerflinger,Amanda E. Au,Timothy R Blackmore,Gerbrand J. van der Heden van Noort,Paul P. Geurink,Huib Ovaa,Janet Newman,Alan Riboldi-Tunnicliffe,Peter E. Czabotar,Jeffrey P Mitchell,Rebecca Feltham,Bernhard C. Lechtenberg,Kym N Lowes,Grant Dewson,Marc Pellegrini,Guillaume Lessene,Guillaume Lessene,David Komander +30 more
TL;DR: Non‐covalent small molecule SARS PLpro inhibitors also target SARS2 PLpro, prevent self‐processing of nsp3 in cells and display high potency and excellent antiviral activity in a SARS‐CoV‐2 infection model.